The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms

被引：202

作者：

Cooper-DeHoff, Rhonda M. ^{[1
,2
,3
]}

Niemi, Mikko ^{[4
,5
,6
]}

Ramsey, Laura B. ^{[7
,8
,9
]}

Luzum, Jasmine A. ^{[10
]}

Tarkiainen, E. Katriina ^{[4
,5
,6
]}

Straka, Robert J. ^{[11
]}

Gong, Li ^{[12
]}

Tuteja, Sony ^{[13
]}

Wilke, Russell A. ^{[14
]}

Wadelius, Mia ^{[15
]}

Larson, Eric A. ^{[14
]}

Roden, Dan M. ^{[16
,17
,18
,19
]}

Klein, Teri E. ^{[12
]}

Yee, Sook Wah ^{[20
]}

Krauss, Ronald M. ^{[21
,22
]}

Turner, Richard M. ^{[23
]}

Palaniappan, Latha ^{[24
]}

Gaedigk, Andrea ^{[25
,26
]}

Giacomini, Kathleen M. ^{[20
]}

Caudle, Kelly E. ^{[27
]}

Voora, Deepak ^{[28
]}

机构：

[1] Univ Florida, Coll Pharm, Dept Pharmacotherapy & Translat Res, Gainesville, FL USA

[2] Univ Florida, Coll Pharm, Ctr Pharmacogen & Precis Med, Gainesville, FL USA

[3] Univ Florida, Coll Med, Dept Med, Div Cardiovasc Med, Gainesville, FL USA

[4] Univ Helsinki, Dept Clin Pharmacol, Individualized Drug Therapy Res Program, Helsinki, Finland

[5] Helsinki Univ Hosp, HUS Diagnost Ctr, Helsinki, Finland

[6] Univ Helsinki, Individualized Drug Therapy Res Program, Helsinki, Finland

[7] Cincinnati Childrens Hosp Med Ctr, Div Clin Pharmacol, Cincinnati, OH 45229 USA

[8] Cincinnati Childrens Hosp Med Ctr, Div Res Patient Serv, Cincinnati, OH 45229 USA

[9] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA

[10] Univ Michigan, Coll Pharm, Dept Clin Pharm, 428 Church St, Ann Arbor, MI 48109 USA

[11] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA

[12] Stanford Univ, Dept Biomed Data Sci, Sch Med, Stanford, CA 94305 USA

[13] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA

[14] Univ South Dakota, Sanford Sch Med, Dept Internal Med, Sioux Falls, SD USA

[15] Uppsala Univ, Dept Med Sci, Clin Pharmacogen & Sci Life Lab, Uppsala, Sweden

[16] Vanderbilt Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Nashville, TN USA

[17] Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN USA

[18] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA

[19] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37232 USA

[20] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA

[21] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA

[22] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[23] Univ Liverpool, Wolfson Ctr Personalised Med, Liverpool, Merseyside, England

[24] Stanford Univ, Sch Med, Div Primary Care & Populat Hlth, Stanford, CA 94305 USA

[25] Childrens Mercy Kansas City, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO USA

[26] Univ Missouri, Sch Med, Kansas City, MO 64108 USA

[27] St Jude Childrens Res Hosp, Dept Pharm & Pharmaceut Sci, Div Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA

[28] Duke Univ, Sch Med, Dept Med, Duke Ctr Appl Genom & Precis Med, Durham, NC 27706 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷 / 05期

基金：

欧洲研究理事会; 美国国家卫生研究院;

关键词：

INDUCED MYOPATHY; PHARMACOKINETICS; RISK; RHABDOMYOLYSIS; VARIANTS; ALLELES; IMPACT;

D O I：

10.1002/cpt.2557

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Statins reduce cholesterol, prevent cardiovascular disease, and are among the most commonly prescribed medications in the world. Statin-associated musculoskeletal symptoms (SAMS) impact statin adherence and ultimately can impede the long-term effectiveness of statin therapy. There are several identified pharmacogenetic variants that impact statin disposition and adverse events during statin therapy. SLCO1B1 encodes a transporter (SLCO1B1; alternative names include OATP1B1 or OATP-C) that facilitates the hepatic uptake of all statins. ABCG2 encodes an efflux transporter (BCRP) that modulates the absorption and disposition of rosuvastatin. CYP2C9 encodes a phase I drug metabolizing enzyme responsible for the oxidation of some statins. Genetic variation in each of these genes alters systemic exposure to statins (i.e., simvastatin, rosuvastatin, pravastatin, pitavastatin, atorvastatin, fluvastatin, lovastatin), which can increase the risk for SAMS. We summarize the literature supporting these associations and provide therapeutic recommendations for statins based on SLCO1B1, ABCG2, and CYP2C9 genotype with the goal of improving the overall safety, adherence, and effectiveness of statin therapy. This document replaces the 2012 and 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for SLCO1B1 and simvastatin-induced myopathy.

引用

页码：1007 / 1021

页数：15

共 49 条

[1] Statin-induced myopathy: a review and update [J].